Sambhawana Bhandari

Dr. Sambhawana Bhandari

Rheumatology, Washington University in St. Louis School of Medicine, St Louis, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2024 in Annals of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
Shashi Bhushan SinghShashi Bhushan Singh
Shashi Bhushan Singh
Sambhawana BhandariSambhawana Bhandari
Sambhawana Bhandari
SBSadikshya Bhandari
Sadikshya Bhandari
SBSamikshya Bhandari
Samikshya Bhandari
RSRajshree Singh
Rajshree Singh
MRMona-Elisabeth Revheim
Mona-Elisabeth Revheim
Rheumatoid Arthritis (RA) is a systemic inflammatory disorder that commonly presents with polyarthritis but can have multisystemic involvement and complications, leading to increased morbidity and mortality. The diagnosis of RA continues to be challenging due to its varied clinical presentations. In this review article, we aim to determine the potential of PET/CT to assist in the diagnosis of RA and its complications, evaluate the therapeutic response to treatment, and predict RA remission. PET/CT has increasingly been used in the last decade to diagnose, monitor treatment response, predict remissions, and diagnose subclinical complications in RA. PET imaging with [18F]-fluorodeoxyglucose ([18F]-FDG) is the most commonly applied radiotracer in RA, but other tracers are also being studied. PET/CT with [18F]-FDG, [18F]-NaF, and other tracers might lead to early identification of RA and timely evidence-based clinical management, decreasing morbidity and mortality. Although PET/CT has been evolving as a promising tool for evaluating and managing RA, more evidence is required before incorporating PET/CT in the standard clinical management of RA.

5 June 2023 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
Sambhawana BhandariSambhawana Bhandari
Sambhawana Bhandari
SBSadikshya Bhandari
Sadikshya Bhandari
SBSamikshya Bhandari
Samikshya Bhandari
Systemic rheumatoid diseases (SRDs) are autoimmune and inflammatory disorders that affect multiple organ systems, impacting patients’ quality of life, and survival rates. Standard treatment requires continuous drug therapy and immunosuppression. Chimeric antigen receptor (CAR) T cell therapy has the potential to target and eliminate pathologically activated immune cells and re-establish tolerance in organs affected by dysregulated immunity, making them a promising treatment option for autoimmune diseases. In autoimmune diseases, CAR T cells have the advantage of being able to kill B cells effectively without the need for an accessory cell type. Additionally, CAR T cells targeting CD19 have shown promise in comprehensive B cell aplasia, preserving pre-existing humoral immunity, and specifically eliminating pathogenic B cells. CAR T cell therapy’s limited use in SRDs is due to its inability to effectively target the various autoreactive lymphocytes present. Researchers are developing a universal CAR T cell therapy that detects and targets autoreactive lymphocytes using major epitope peptides, though further studies are required. Moreover, adoptive transfer of CAR-Tregs has shown promise for effectively reducing inflammation and treating autoimmunity. Through this exploration, the authors hope to provide a comprehensive understanding of the current state of research on this topic, identify areas for further study, and promote the advancement of CAR T cell therapy as a treatment option for SRDs.

27 June 2022 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
Sambhawana BhandariSambhawana Bhandari
Sambhawana Bhandari
MBMaun Ranjan Baral
Maun Ranjan Baral
MBMatthew Barbery
Matthew Barbery
ARAlla Rudinskaya
Alla Rudinskaya
OSOleg Sostin
Oleg Sostin

28 February 2024 in Rheumato
Verified
Journal Article
Open access
PDF file
Sambhawana BhandariSambhawana Bhandari
Sambhawana Bhandari
LZLisa Zickuhr
Lisa Zickuhr
MBMaun Ranjan Baral
Maun Ranjan Baral
SBSanjeev Bhalla
Sanjeev Bhalla
HJHeather Jones
Heather Jones
DSDeepali Sen
Deepali Sen
Anti-melanoma differentiation-associated gene 5 (MDA-5) dermatomyositis (DM) is noteworthy for its association with rapidly progressive interstitial lung disease (RP-ILD), vasculopathy, and distinctive cutaneous features. First identified in a Japanese cohort in 2005, MDA-5 DM carries a significant mortality risk, emphasizing the crucial need for early diagnosis. This review explores the pathogenesis, clinical presentation, diagnosis, management, and prognosis of MDA-5 DM and ILD and includes new research and recommendations regarding disease management.

24 November 2021 in Cureus
Verified
Journal Article
Open access
Sambhawana BhandariSambhawana Bhandari
Sambhawana Bhandari
MBMaun R Baral
Maun R Baral
JZJorge Aguilar Zanatta
Jorge Aguilar Zanatta
Antipsychotics are a widely used class of drugs. They have been frequently associated with temperature dysregulation, especially hyperthermia. Hypothermia is also a rare but very serious side effect associated with these drugs. We present a case of possible aripiprazole-induced hypothermia with normothermia achieved after its discontinuation. An 81-year-old woman was brought into the emergency room with hypotension, hypothermia, and bradycardia. She was initially managed with intravenous fluids, external rewarming, and broad-spectrum antibiotics. Blood cultures and workup for infection returned negative with a low procalcitonin. Workup for endocrinopathy was also negative. She needed a Bair Hugger™ (3M, Maplewood, MN) to keep her temperature above 36 °C even after her other vital signs had normalized. Finally, her aripiprazole was held with the suspicion that it was causing hypothermia. Following this, her temperature improved and remained stable throughout even after discharge. Since hypothermia can be life-threatening, after ruling out common causes, clinicians should consider aripiprazole-induced hypothermia in these patients and the drug should be promptly discontinued.

8 November 2021 in Cureus
Verified
Journal Article
Open access
Sambhawana BhandariSambhawana Bhandari
Sambhawana Bhandari
MBMaun R Baral
Maun R Baral
CSChristian Espana Schmidt
Christian Espana Schmidt
The elderly have a higher incidence of ischemic stroke along with higher mortality and morbidity compared to their younger counterparts. However, though studies have included people >85 or 90 years of age, there haven’t been reports of many individuals above 100 years of age. Among the oldest old, the oldest age studied for alteplase administration is possibly 101 years. We present a case of a 105-year-old woman with a medical history of a cerebrovascular accident in 2018 for which she received thrombolytic therapy with residual slurred speech and mild dysphagia. She was brought in from her nursing facility for worsening of slurred speech and right facial droop that began two hours before presentation to the emergency department. She was found to have aphasia, left-sided gaze preference, and upper motor neuron dysfunction of her right arm associated with drift. Her National Institutes of Health Stroke Scale (NIHSS) score at presentation was 17. An urgent CT scan of the head was performed that did not show any evidence of acute bleeding. CT angiogram of brain and neck was unremarkable with no evidence of high-grade stenosis, aneurysm, occlusion, or dissection. With the negative CT findings, the patient received thrombolytic therapy with alteplase. She was monitored in the intensive care unit for 24 hours after alteplase administration with neurological checks every one hour. The repeated CT head after 24 hours was negative for any hemorrhage. She was discharged after two days of hospital admission and her NIHSS score on the day of discharge was 4. Our patient was 105 years old, which is arguably one of the oldest ages to receive alteplase. Her NIHSS score improved considerably and she did not suffer from hemorrhagic complications.